Researchers have demonstrated that the inhibition of SYK can abrogate hepatic neutrophil infiltration and activation of resident immune cells induced by alcohol, and diminish alcohol-induced hepatic steatosis and apoptosis via NFκB signaling pathway, indicating the potential of SYK as a therapeutic target in human alcoholic steatohepatitis treatment (Figure 2C) [41, 53]. Here, SYK is linked to alcoholic fatty liver disease.